New imaging method could spot hidden cancers

NCT ID NCT02307630

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time points. The goal is to learn about the antibody's distribution and how long it stays in the body, which could improve cancer imaging in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
124I-Humanized 3F8 (a radioactive antibody)
What this could lead to
If successful, this could lead to better PET scans for detecting certain solid tumors, helping doctors see where the cancer is more clearly.
What could go wrong
This is a very small pilot study with only 7 participants, so results may not apply to everyone. It is designed to test imaging, not to treat or cure cancer, so no direct benefit is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.